Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleMETABOLISM, TRANSPORT, AND PHARMACOGENOMICS

Ritonavir, Saquinavir, and Efavirenz, but Not Nevirapine, Inhibit Bile Acid Transport in Human and Rat Hepatocytes

Mary Peace McRae, Carolina M. Lowe, Xianbin Tian, David L. Bourdet, Richard H. Ho, Brenda F. Leake, Richard B. Kim, Kim L. R. Brouwer and Angela D. M. Kashuba
Journal of Pharmacology and Experimental Therapeutics September 2006, 318 (3) 1068-1075; DOI: https://doi.org/10.1124/jpet.106.102657
Mary Peace McRae
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolina M. Lowe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xianbin Tian
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David L. Bourdet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard H. Ho
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brenda F. Leake
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard B. Kim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim L. R. Brouwer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angela D. M. Kashuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Human immunodeficiency virus-infected patients on antiretroviral drug therapy frequently experience hepatotoxicity, the underlying mechanism of which is poorly understood. Hepatotoxicity from other compounds such as bosentan and troglitazone has been attributed, in part, to inhibition of hepatocyte bile acid excretion. This work tested the hypothesis that antiretroviral drugs modulate hepatic bile acid transport. Ritonavir (28 μM), saquinavir (15 μM), and efavirenz (32 μM) inhibited [3H]taurocholate transport in bile salt export pump expressing Sf9-derived membrane vesicles by 90, 71, and 33%, respectively. In sandwich-cultured human hepatocytes, the biliary excretion index (BEI) of [3H]taurocholate was maximally decreased 59% by ritonavir, 39% by saquinavir, and 20% by efavirenz. Likewise, in sandwich-cultured rat hepatocytes, the BEI of [3H]taurocholate was decreased 100% by ritonavir and 94% by saquinavir. Sodium-dependent and -independent initial uptake rates of [3H]taurocholate in suspended rat hepatocytes were significantly decreased by ritonavir, saquinavir, and efavirenz. [3H]Taurocholate transport by recombinant NTCP and Ntcp was inhibited by ritonavir (IC50 = 2.1 and 6.4 μM in human and rat, respectively), saquinavir (IC50 = 6.7 and 20 μM, respectively), and efavirenz (IC50 = 43 and 97 μM, respectively). Nevirapine (75 μM) had no effect on bile acid transport in any model system. In conclusion, ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibited both the hepatic uptake and biliary excretion of taurocholate.

Footnotes

  • This work was supported in part by a 2003 to 2004 developmental grant from the University of North Carolina at Chapel Hill Center for AIDS Research, by a National Institutes of Health-funded program (9P30 AI 50410-04), and by National Institutes of Health Grants GM41935, CA106101, GM54724, GM31304, and AI54980. M.P.M. is the recipient of an American Foundation for Pharmaceutical Education predoctoral fellowship.

  • A portion of this work was previously presented: McRae MP, Brouwer KLR, and Kashuba ADM (2004) Effects of ritonavir and nevirapine on hepatic transport and biliary excretion index of taurocholate in sandwich-cultured primary human and rat hepatocytes. International Society for the Study of Xenobiotics Annual Meeting; 2004 Aug 29–Sept 2; Vancouver, BC, Canada. pp 475, International Society for the Study of Xenobiotics, Washington, DC; and McRae MP, Bourdet DL, Kim RB, Brouwer KLR, and Kashuba ADM (2004) The antiretrovirals ritonavir, saquinavir and efavirenz, but not nevirapine, inhibit taurocholate uptake in NTCP-injected oocytes, PT2337. American Association of Pharmaceutical Scientists Annual Meeting; 2004 Nov 7–11; Baltimore, MD. American Association of Pharmaceutical Scientists, Arlington, VA.

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.106.102657.

  • ABBREVIATIONS: BSEP, bile salt export pump; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; GFP, green fluorescence protein; HBSS, Hanks' balanced salt solution; BEI, biliary excretion index; NTCP, sodium-dependent taurocholate-cotransporting polypeptide; OATP, organic anion-transporting polypeptide.

    • Received February 24, 2006.
    • Accepted May 22, 2006.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 377 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 377, Issue 2
1 May 2021
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Ritonavir, Saquinavir, and Efavirenz, but Not Nevirapine, Inhibit Bile Acid Transport in Human and Rat Hepatocytes
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleMETABOLISM, TRANSPORT, AND PHARMACOGENOMICS

Ritonavir, Saquinavir, and Efavirenz, but Not Nevirapine, Inhibit Bile Acid Transport in Human and Rat Hepatocytes

Mary Peace McRae, Carolina M. Lowe, Xianbin Tian, David L. Bourdet, Richard H. Ho, Brenda F. Leake, Richard B. Kim, Kim L. R. Brouwer and Angela D. M. Kashuba
Journal of Pharmacology and Experimental Therapeutics September 1, 2006, 318 (3) 1068-1075; DOI: https://doi.org/10.1124/jpet.106.102657

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleMETABOLISM, TRANSPORT, AND PHARMACOGENOMICS

Ritonavir, Saquinavir, and Efavirenz, but Not Nevirapine, Inhibit Bile Acid Transport in Human and Rat Hepatocytes

Mary Peace McRae, Carolina M. Lowe, Xianbin Tian, David L. Bourdet, Richard H. Ho, Brenda F. Leake, Richard B. Kim, Kim L. R. Brouwer and Angela D. M. Kashuba
Journal of Pharmacology and Experimental Therapeutics September 1, 2006, 318 (3) 1068-1075; DOI: https://doi.org/10.1124/jpet.106.102657
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • HDL Mimetic 4F Modulates Aβ Distribution in Brain and Plasma
  • AOX1 Inhibition by Gefitinib, Erlotinib, and Metabolites
  • Catalytic Activity of CYP2C9 Variants
Show more Metabolism, Transport, and Pharmacogenomics

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics